Management of Adverse Events with First-Line Combination Therapies for EGFR-mutated NSCLC

An expert discusses the safety profiles of combination regimens, effective strategies for managing side effects, and how to weigh the potential for toxicity versus efficacy/benefits when discussing treatment options with patients.

EP: 1.A 55-Year-Old Man with EGFR-mutated Advanced/Metastatic NSCLC

EP: 2.Recent Advances in First-Line Combination Therapy for EGFR-mutated Metastatic NSCLC: Exploring Amivantamab + Lazertinib and Osimertinib-Based Regimens

EP: 3.An Academic Perspective to Making First-Line Treatment Decisions for EGFR-mutated Metastatic NSCLC

EP: 4.First-Line Treatment Approaches for EGFR-mutated Metastatic NSCLC: Updates from MARIPOSA High-Risk Analyses

Now Viewing

EP: 5.Management of Adverse Events with First-Line Combination Therapies for EGFR-mutated NSCLC

EP: 6.Considerations for Treatment of Advanced/Metastatic EGFR-mutated NSCLC

• Please discuss safety profiles of combination regimens. What are effective strategies for management?
• How do you weigh the potential for toxicity vs efficacy/benefits when discussing combination treatment options with your patients?

Recent Videos